Angelini Pharma Enters Into An Exclusive Option Agreement
The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1...
The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1...